JO3021B1 - احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد - Google Patents

احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد

Info

Publication number
JO3021B1
JO3021B1 JOP/2007/0423A JOP20070423A JO3021B1 JO 3021 B1 JO3021 B1 JO 3021B1 JO P20070423 A JOP20070423 A JO P20070423A JO 3021 B1 JO3021 B1 JO 3021B1
Authority
JO
Jordan
Prior art keywords
lamino
methylpyridine
fluoromethyl
carbamoyl
trifluoromethyl
Prior art date
Application number
JOP/2007/0423A
Other languages
English (en)
Inventor
Alfons Grunenberg Dr
Katharina Tenbieg Dr
Stiehl Juergen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38972960&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3021(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JO3021B1 publication Critical patent/JO3021B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق هذا الاختراع باحادي هيدرات 4-[4-({4-كلورو-3- ( ثلاثي فلورو ميثيل) فنيل] كربامويل} امينو) -3- فلورو فينوكسي] – N ميثيل بيريدين- 20 كربوكسامبد وبطرق لتحضيره وبمستحضرات صيدليه تشتمل عليه وباستخدامه في السيطرة على اعتلالات واضطرابات disorders,
JOP/2007/0423A 2006-10-11 2007-10-07 احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد JO3021B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06021296 2006-10-11

Publications (1)

Publication Number Publication Date
JO3021B1 true JO3021B1 (ar) 2016-09-05

Family

ID=38972960

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0423A JO3021B1 (ar) 2006-10-11 2007-10-07 احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد

Country Status (38)

Country Link
US (3) US9957232B2 (ar)
EP (1) EP2097381B1 (ar)
JP (1) JP5346293B2 (ar)
KR (1) KR101418623B1 (ar)
CN (1) CN101547903B (ar)
AR (1) AR062927A1 (ar)
AU (1) AU2007306716B2 (ar)
BR (1) BRPI0719828B1 (ar)
CA (1) CA2666170C (ar)
CL (1) CL2007002930A1 (ar)
CO (1) CO6150132A2 (ar)
CR (1) CR10663A (ar)
CY (1) CY1114637T1 (ar)
DK (1) DK2097381T3 (ar)
ES (1) ES2427358T3 (ar)
GT (1) GT200900057A (ar)
HK (1) HK1136287A1 (ar)
HN (1) HN2009000499A (ar)
IL (1) IL197369A (ar)
JO (1) JO3021B1 (ar)
MA (1) MA30878B1 (ar)
MX (1) MX2009002642A (ar)
MY (1) MY152595A (ar)
NZ (1) NZ576153A (ar)
PA (1) PA8750301A1 (ar)
PE (1) PE20081459A1 (ar)
PL (1) PL2097381T3 (ar)
PT (1) PT2097381E (ar)
RU (1) RU2466992C2 (ar)
SG (1) SG175584A1 (ar)
SI (1) SI2097381T1 (ar)
SV (1) SV2009003187A (ar)
TN (1) TN2009000072A1 (ar)
TW (1) TWI428322B (ar)
UA (1) UA95984C2 (ar)
UY (1) UY30633A1 (ar)
WO (1) WO2008043446A1 (ar)
ZA (1) ZA200902469B (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1626714E (pt) * 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
ES2387812T3 (es) * 2004-09-29 2012-10-02 Bayer Pharma Aktiengesellschaft Forma termodinámicamente estable del tosilato BAY 43-9006
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2669158A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
AU2015201426B2 (en) * 2010-04-15 2016-07-07 Bayer Healthcare Llc Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CA2805874A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
SG189038A1 (en) 2010-10-01 2013-05-31 Bayer Ip Gmbh Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
PE20141031A1 (es) * 2011-06-28 2014-08-21 Bayer Healthcare Llc Composicion farmaceutica oftalmologica topica que contiene regorafenib
UY35006A (es) 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
HUE039878T2 (hu) 2012-09-25 2019-02-28 Bayer Pharma AG Regorafenib és acetilszalicilsav kombinációja kolorektális rák kezelésére
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
IN2013CH04511A (ar) * 2013-10-04 2015-04-10 Hetero Research Foundation
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
WO2016005874A1 (en) 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
WO2016038590A1 (en) 2014-09-12 2016-03-17 Mylan Laboratories Ltd Process for the preparation of crystalline form i of regorafenib
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
CN105985287B (zh) * 2015-02-13 2018-07-17 上海京新生物医药有限公司 一种瑞戈非尼新晶型
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
DK3630112T3 (da) 2017-06-02 2024-04-22 Bayer Healthcare Llc Kombination af regorafenib og nivolumab til behandling af cancer
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN111995571B (zh) * 2020-08-07 2021-12-03 天津理工大学 一种瑞戈非尼与马来酸的共晶及其制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6705789A (ar) 1967-03-08 1968-09-09
US4223153A (en) 1979-02-09 1980-09-16 Eli Lilly And Company Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
NZ220764A (en) 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US4835180A (en) 1986-10-02 1989-05-30 Sterling Drug Inc. N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5629425A (en) 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
CO4410191A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
TR199900639T2 (xx) 1996-09-23 1999-06-21 Eli Lilly And Company Olanzapin dihidrat D.
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
IN190389B (ar) 1999-07-14 2003-07-26 Ranbaxy Lab Ltd
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ES2275931T5 (es) 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
US20080108672A1 (en) 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928277B1 (en) 2002-02-11 2011-04-19 Cox Jr Henry Wilmore Method for reducing contamination
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
CA2475818C (en) 2002-02-11 2011-07-19 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
JP4300184B2 (ja) 2002-05-03 2009-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリマー性マイクロエマルション
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
EP1678123A1 (en) 2003-10-15 2006-07-12 Bayer HealthCare AG Tetrahydro-naphthalene and urea derivatives
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2005110994A2 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EP1796642B1 (en) 2004-08-27 2008-05-21 Bayer Pharmaceuticals Corporation Pharmaceutical compositions in the form of solid dispersions for the treatment of cancer
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CN101052619B (zh) 2004-09-29 2012-02-22 拜耳先灵制药股份公司 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法
ES2387812T3 (es) 2004-09-29 2012-10-02 Bayer Pharma Aktiengesellschaft Forma termodinámicamente estable del tosilato BAY 43-9006
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
US20090306020A1 (en) 2005-05-27 2009-12-10 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
CA2609389A1 (en) 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
KR20080073711A (ko) 2005-10-21 2008-08-11 바이엘 헬스케어 엘엘씨 암의 예측 및 예후 방법, 및 암 치료 모니터링 방법
WO2007053573A2 (en) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
EP2289515A3 (en) 2005-10-31 2012-04-11 Bayer HealthCare LLC Combinations comprising a diaryl urea and an interferon
EP1946116A4 (en) 2005-11-02 2010-01-06 Bayer Healthcare Llc METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY
JP5084736B2 (ja) 2005-11-10 2012-11-28 バイエル・ファルマ・アクチェンゲゼルシャフト 肺高血圧を処置するためのジアリールウレア
BRPI0618524A2 (pt) 2005-11-10 2011-09-06 Bayer Schering Pharma Ag uso de diaril ureias para o tratamento de hipertensão pulmonar, bem como combinação e composição compreendendo as referidas diaril ureias e uso da combinação
CA2629863A1 (en) 2005-11-14 2007-05-24 Scott Wilhelm Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors
AU2006315592A1 (en) 2005-11-14 2007-05-24 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20110195110A1 (en) 2005-12-01 2011-08-11 Roger Smith Urea compounds useful in the treatment of cancer
US20090227637A1 (en) 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
JP2009519265A (ja) 2005-12-15 2009-05-14 バイエル・ヘルスケア・アクチェンゲゼルシャフト ウイルス感染を処置するためのジアリールウレア
CA2633417A1 (en) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
EP1973897B1 (en) 2005-12-21 2014-05-21 Bayer Intellectual Property GmbH Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
MX2008014953A (es) 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2668748A1 (en) 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
CA2669158A1 (en) 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
DK2111401T3 (da) 2006-12-20 2011-05-30 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer
ATE528286T1 (de) 2006-12-20 2011-10-15 Bayer Healthcare Llc 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs
WO2008089388A2 (en) 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
US8680124B2 (en) 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
EP2231612A1 (en) 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
CA2729041A1 (en) 2008-06-25 2009-12-30 Barbara Albrecht-Kuepper Diaryl urea for treating heart failure
US20110257035A1 (en) 2008-10-21 2011-10-20 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
WO2011036648A1 (en) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
EP2499116A1 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011146725A1 (en) 2010-05-19 2011-11-24 Bayer Healthcare Llc Biomarkers for a multikinase inhibitor
CA2805874A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Also Published As

Publication number Publication date
BRPI0719828A2 (pt) 2014-02-04
ES2427358T3 (es) 2013-10-30
DK2097381T3 (da) 2013-09-23
AR062927A1 (es) 2008-12-17
NZ576153A (en) 2012-02-24
SI2097381T1 (sl) 2013-11-29
JP2010505888A (ja) 2010-02-25
KR20090061043A (ko) 2009-06-15
GT200900057A (es) 2009-12-09
AU2007306716B2 (en) 2013-06-20
WO2008043446A1 (en) 2008-04-17
IL197369A (en) 2015-06-30
SV2009003187A (es) 2009-11-26
US9957232B2 (en) 2018-05-01
ZA200902469B (en) 2010-06-30
CR10663A (es) 2009-07-31
EP2097381B1 (en) 2013-06-19
TWI428322B (zh) 2014-03-01
AU2007306716A1 (en) 2008-04-17
UY30633A1 (es) 2008-05-31
CN101547903A (zh) 2009-09-30
CA2666170A1 (en) 2008-04-17
US20100173953A1 (en) 2010-07-08
PA8750301A1 (es) 2009-01-23
KR101418623B1 (ko) 2014-07-14
TW200831465A (en) 2008-08-01
HK1136287A1 (en) 2010-06-25
TN2009000072A1 (en) 2010-08-19
BRPI0719828B1 (pt) 2022-05-17
CO6150132A2 (es) 2010-04-20
PL2097381T3 (pl) 2013-11-29
JP5346293B2 (ja) 2013-11-20
IL197369A0 (en) 2009-12-24
CA2666170C (en) 2016-05-24
SG175584A1 (en) 2011-11-28
CY1114637T1 (el) 2016-10-05
CL2007002930A1 (es) 2008-04-04
MX2009002642A (es) 2009-05-28
PE20081459A1 (es) 2008-12-18
MY152595A (en) 2014-10-31
EP2097381A1 (en) 2009-09-09
MA30878B1 (fr) 2009-11-02
RU2009117388A (ru) 2010-11-20
RU2466992C2 (ru) 2012-11-20
HN2009000499A (es) 2012-03-07
US20140315958A1 (en) 2014-10-23
US20180194730A1 (en) 2018-07-12
CN101547903B (zh) 2014-01-15
PT2097381E (pt) 2013-09-17
UA95984C2 (en) 2011-09-26

Similar Documents

Publication Publication Date Title
JO3021B1 (ar) احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد
LTC1793824I2 (lt) Naujos farmacinės kompozicijos, apimančios 4-(4-(3-(4-chlor-3-trifluormetilfenil)ureido)-3-fluorfenoksi)piridin-2-karboksirūgštį, hiperproliferacinių sutrikimų gydymui
TNSN07048A1 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
UA92349C2 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
SG155996A1 (en) Thermodynamically stable form of bay 43-9006 tosylate
IL194850A (en) Benzoazepine-oxy-acetic acid derivatives used as delta-ppar agonists for raising c-hdl levels, lowering c-ldl levels, and lowering cholesterol levels and their pharmacological compounds
NO20090628L (no) Pyridizinon derivativater
WO2007125103A3 (en) Benzamide glucokinase activators
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
JO2973B1 (ar) ملح فيوميريت ل(الفا اس، بيتا ار)-6-برومو-الفا-[2-(ميثيل امينو)ايثيل] -2- ميثوكسي -الفا-1- نفثالينيل- بيتا- فينيل-3- كوينولين ايثانول
WO2007125105A3 (en) Benzamide glucokinase activators
WO2009134574A3 (en) Disubstituted phthalazine hedgehog pathway antagonists
WO2008153752A3 (en) Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2007090749A3 (en) Benzamide and heteroarene derivatives as cetp inhibitors
WO2003062191A8 (en) N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
IL188438A (en) A heterocyclic active drug with five benzoposes, or a pharmaceutically acceptable salt and aster salts product, as well as compounds containing them and their use as @catol - o @ - @ of @ enzyme @ dead G iltransferase @@ comtI
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
WO2006116349A3 (en) Sustained release formulation and dosing schedules of leukotriene synthesis inhibitor for human therapy
NZ596000A (en) Carboxamide compounds and their use as calpain inhibitors
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
IL195632A0 (en) Substituted carboxamides